Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
| 25.07 | |
| 25.07 | |
| - | |
| 25.07 | |
| 25.07 | |
| 20.6153-25.96 | |
| 5 812 M | |
| 29.4941 | |
| 222 M | |
| 3 017 M | |
| 0.5345 | |
| 0.0315 | |
| 0.414 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Key Insights Significantly high institutional ownership implies Hikma Pharmaceuticals' stock price is sensitive to their trading actions 50% of the business is held by the top 13 shareholders Insider...
As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your hand at stock picking, you risk returning less than the market. Unfortunately, that's b...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
